UBS Group »

Acrivon Therapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Acrivon Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Acrivon Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acrivon Therapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2024-03-31 $91k 13k 7.15
2023-09-30 $974 102 9.56
2023-06-30 $127k 9.8k 13.00
2023-03-31 $68k 5.4k 12.68
2022-12-31 $55k 4.7k 11.52